Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Diabetes Stocks To Buy Now

In this article, we discuss the 10 best diabetes stocks to buy now. If you want to read about some more diabetes stocks, go directly to 5 Best Diabetes Stocks To Buy Now.

The diabetes market has grown in the past few years as organizations and individuals in the private and public domains make significant investments in the sector to generate awareness about early and precise disease diagnosis and treatment. This is because diabetes has become an increasingly prevalent disease in both emerging and developed economies. Per a report by Global Market Insights, the diabetes care devices market alone, which does not take into account the drugs market for the diseases, will be worth $80 billion by the end of this decade. 

The use of efficient devices to treat diabetes, such as vials and syringes, insulin pens, and insulin pumps to deliver insulin subcutaneously, partly due to increasing incidences of diabetes among the elderly, is one of the reasons that may encourage the faster adoption of diabetes products. Another contributing factor to the diabetes market is the emerging self-monitoring and self-administration trends that are likely to create new growth avenues for the diabetes care devices industry and act as a catalyst for pharma stocks. 

Some of the top stocks that benefit from diabetes care drugs and devices include Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV). According to a study by Pharma Web, the use of non-insulin treatments for the treatment of diabetes is also on the rise. These include oral medications, lifestyle changes, and other treatments. As diabetes remains one of the fastest-growing diseases across the world, the biggest healthcare companies are likely to keep pouring billions into the development of drugs for treatment. 

Our Methodology

The companies that operate in the pharma sector and have diabetes drugs in the market or under development were selected for the list. In order to provide readers with some context for their investment choices, the business fundamentals and analyst ratings for the stocks are also discussed. Data from around 900 elite hedge funds tracked by Insider Monkey in the second quarter of 2022 was used to identify the number of hedge funds that hold stakes in each firm.

Pixabay/Public Domain

Best Diabetes Stocks To Buy Now

10. Novartis AG (NYSE:NVS)

Number of Hedge Fund Holders: 22 

Novartis AG (NYSE:NVS) researches, develops, manufactures, and markets healthcare products worldwide. It is one of the premier diabetes stocks to invest in. On September 22, the company announced that it will focus on five therapeutic areas — cardiovascular, immunology, neuroscience, solid tumors, and hematology  — as part of a larger transformation plan to become a significant player in the United States pharma market in the next five years. The firm said it intends to stick to the plan despite recent laws to control drug prices.

On September 7, investment advisory Kepler Cheuvreux upgraded Novartis AG (NYSE:NVS) stock to Buy from Hold with a price target of CHF 90. Analyst David Evans issued the ratings update. 

Among the hedge funds being tracked by Insider Monkey, Washington-based investment firm Fisher Asset Management is a leading shareholder in Novartis AG (NYSE:NVS), with 11 million shares worth more than $950 million.

Just like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Novartis AG (NYSE:NVS) is one of the best diabetes stocks to buy now according to hedge funds. 

9. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders: 32    

Novo Nordisk A/S (NYSE:NVO) is a healthcare company that engages in the research, development, manufacture, and marketing of pharmaceutical products. It is one of the top diabetes stocks to invest in. On September 22, the firm revealed that data from a phase 3 trial of Tresiba, a once-daily therapy for diabetes being developed by the firm, showed that more people with type 2 diabetes achieved blood sugar targets. The study evaluated once-weekly insulin icodec versus once-daily insulin degludec in 526 people with type 2 diabetes.

On August 4, investment advisory Barclays kept an Overweight rating on Novo Nordisk A/S (NYSE:NVO) stock and lowered the price target to DKK 825 from DKK 875. Analyst Emmanuel Papadakis issued the ratings update. 

At the end of the second quarter of 2022, 32 hedge funds in the database of Insider Monkey held stakes worth $4.4 billion in Novo Nordisk A/S (NYSE:NVO), compared to 31 the preceding quarter worth $4.5 billion.

In its Q2 2022 investor letter, Baron Funds, an asset management firm, highlighted a few stocks and Novo Nordisk A/S (NYSE:NVO) was one of them. Here is what the fund said:

“We added to our position in Novo Nordisk A/S (NYSE:NVO), a leading global biopharmaceutical company headquartered in Denmark that specializes in treatments for diabetes, obesity, and other chronic diseases. We wrote about Novo Nordisk in last quarter’s letter. We continue to believe Novo Nordisk’s diabetes and anti-obesity franchise will drive attractive revenue and earnings growth for many years to come. We think both Novo Nordisk and competitor Eli Lilly and Company (which we also own in the Fund) can be successful in these large markets.”

8. Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Number of Hedge Fund Holders: 32  

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is a medical device company that designs, develops, and commercializes various products for people with insulin-dependent diabetes. The firm is among the best diabetes stocks to invest in. In early June, the company revealed data that showed the benefits of using a new insulin pump being developed by the firm that uses cutting-edge Control-IQ technology. The company said the patient-reported outcomes from an ethnically diverse cohort of 1,306 adults showed significant improvements in life quality. 

On August 4, Craig-Hallum analyst Alexander Nowak maintained a Buy rating on Tandem Diabetes Care, Inc. (NASDAQ:TNDM) stock and lowered the price target to $105 from $156, noting that Q2 marked a much different tone from Tandem than the prior period. 

At the end of the second quarter of 2022, 32 hedge funds in the database of Insider Monkey held stakes worth $147.8 million in Tandem Diabetes Care, Inc. (NASDAQ:TNDM), compared to 42 in the preceding quarter worth $385.6 million.

7. Insulet Corporation (NASDAQ:PODD)

Number of Hedge Fund Holders: 34     

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin diabetes systems for people with insulin-dependent diabetes. The company is one of the most prominent diabetes stocks to invest in. In late August, the firm announced that it had won regulatory approval from authorities in the United States for the Omnipod 5 Automated Insulin Delivery System for use in children aged 2 to 5 years with type 1 diabetes. The product is the first tubeless AID system available for preschool children in the US. 

On August 5, Canaccord analyst Kyle Rose maintained a Buy rating on Insulet Corporation (NASDAQ:PODD) stock and raised the price target to $290 from $250, noting the launch of new products by the firm will magnify the competitive advantage of the pharmacy channel. 

Among the hedge funds being tracked by Insider Monkey, California-based investment firm D1 Capital Partners is a leading shareholder in Insulet Corporation (NASDAQ:PODD), with 1.2 million shares worth more than $269 million. 

In its Q1 2022 investor letter, ClearBridge Investments, an asset management firm, highlighted a few stocks and Insulet Corporation (NASDAQ:PODD) was one of them. Here is what the fund said:

“Health care has always been a core foundation of the portfolio and we have been diversifying our health care exposure to include services and solutions beyond our traditional overweight to biopharmaceuticals and managed care. We first purchased Insulet Corporation (NASDAQ:PODD), a leading provider of insulin pumps for diabetes patients, in the fourth quarter of 2021, and we have aggressively added to the position since then. The company is currently the only meaningful manufacturer of patch pumps, the preferred form factor for many patients as compared to traditional tubed pumps. We believe Insulet has a long runway for growth given its large and underpenetrated market, which is only one-third penetrated in Type 1 diabetes and low-single-digit penetrated in the insulin- intensive Type 2 diabetes population. Additionally, we see the launch of the company’s next generation offering, Omnipod 5, which received FDA clearance in January, as an accelerant to growth. Insulet has strong gross margins and is profitable today, though we still see room for significant operating margin expansion ahead.”

6. AstraZeneca PLC (NASDAQ:AZN)

Number of Hedge Fund Holders: 47    

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. The firm features on the list of best diabetes stocks to invest in. One of the premier diabetes drugs of the firm is Exenatide, approved for use in the US  for adult patients with type 2 diabetes. Last year, a study related to the drug showed that patients who received a once-weekly dose of Exenatide showed significantly reduced levels of HbA1c, a blood sugar measure. 

On August 29, Argus analyst Jasper Hellwe upgraded AstraZeneca PLC (NASDAQ:AZN) stock to Buy from Hold with a price target of $75, noting the firm had a range of new drugs approved in the past few months. 

At the end of the second quarter of 2022, 47 hedge funds in the database of Insider Monkey held stakes worth $4.9 billion in AstraZeneca PLC (NASDAQ:AZN), compared to 45 in the previous quarter worth $4.6 billion.

Along with Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN) is one of the best diabetes stocks to buy now according to hedge funds. 

In its Q1 2022 investor letter, Carillon Tower Advisers, an asset management firm, highlighted a few stocks and AstraZeneca PLC (NASDAQ:AZN) was one of them. Here is what the fund said:

“AstraZeneca (NYSE:AZN) performed strongly and reported encouraging fourth-quarter earnings and initial 2022 guidance. AstraZeneca also announced positive clinical data for two drugs within its oncology business that should serve as important long-term growth drivers.”

Click to continue reading and see 5 Best Diabetes Stocks To Buy Now.

Suggested Articles:

Disclosure. None. 10 Best Diabetes Stocks To Buy Now is originally published on Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!